by SD-AbarceoPharma | Apr 30, 2026 | Diabetes, Events, Investors, News & Press releases
Abarceo is participating in the upcoming Redeye Theme Event Diabetes 2026! We’re proud to present Abarceo at the main diabetes business and finance event in Sweden, The Redeye Theme Event Diabetes 2026 on May 6! This focused seminar is intended to give investors...
by SD-AbarceoPharma | Mar 29, 2026 | Diabetes, Events, News & Press releases
23 March Abarceo attended RESI Premier Financing Event to meet investors and partners, interested in changing the diabetes therapeutics field. Abarceo presented it’s aim to release the first oral treatment for Type 1 Diabetes and the first drug providing...
by SD-AbarceoPharma | Mar 29, 2026 | Diabetes, Events, News & Press releases
11–14 March Abarceo attended the ATTD in Barcelona. Abarceo promoted its development to become the first company to provide the diabetes community with a drug that will adress major hallmarks of diabetes. That is including restoration of patients own insulin...
by SD-AbarceoPharma | Nov 14, 2025 | Diabetes, News & Press releases
On World Diabetes Day, we at Abarceo Pharma AB stand with the millions of people around the world living with type 1 diabetes – a chronic autoimmune disease with no apparent treatment. Abarceo pledges to bring a new, disease modifying, treatment to type -1 and type -2...
by SD-AbarceoPharma | Nov 13, 2025 | Diabetes, Events, News & Press releases
Abarceo attended the Nordic Life Science Days in Gothenburgh on October 13–14, 2025. Two days of instense partnering and finance discussions. Abarceo where happy to present the marvelous development of Abarceo Pharma in Mitochondrial repair and the Type 1 Diabetes...
by SD-AbarceoPharma | Sep 26, 2025 | Diabetes, Events, News & Press releases
On September 23, BioStock’s event Investing in Life Science 2025 took place in Stockholm. It was a day full of insights, inspiration, innovation and panel discussions. Abarceo’s CEO Adam Bruce attended the event and presented Abarceo’s development...
Recent Comments